Patents Assigned to VIROGIN BIOTECH CANADA LTD
  • Oncolytic viral vectors and uses thereof
    Patent number: 12208126
    Abstract: Oncolytic viral vectors that incorporate one or more of the following features: viral replication restriction by insertion of microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle. Such viral vectors can be used for the treatment and prevention of cancer.
    Type: Grant
    Filed: February 7, 2023
    Date of Patent: January 28, 2025
    Assignee: Virogin Biotech Canada Ltd.
    Inventors: Mitchell H. Finer, Lorena Lerner, Christophe Quéva, Edward Kennedy
  • Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
    Patent number: 12162919
    Abstract: An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: December 10, 2024
    Assignee: Virogin Biotech Canada Ltd
    Inventors: William Jia, Guoyu Liu, Erica Lee, Dmitry Chouljenko, Jun Ding
  • Oncolytic viral delivery of therapeutic polypeptides
    Patent number: 11865081
    Abstract: Described herein are oncolytic viruses comprising one or more nucleic acids encoding an engager molecule. In some embodiments, the oncolytic viruses comprise one or more nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the oncolytic virus and methods of treating cancer using the oncolytic viruses are further provided herein.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: January 9, 2024
    Assignee: Virogin Biotech Canada Ltd.
    Inventors: Mitchell H. Finer, Luke Evnin
  • Compositions and methods for inhibiting CD279 interactions
    Patent number: 10590169
    Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 17, 2020
    Assignee: Virogin Biotech Canada Ltd
    Inventors: William Jia, Xuexian Bu, I-Fang Lee
  • COMPOSITIONS AND METHODS OF USING STAT1/3 INHIBITORS WITH ONCOLYTIC HERPES VIRUS
    Publication number: 20190307820
    Abstract: The present disclosure relates to the use of an oncolytic virus, such as HSV, and a STAT1/3 inhibitor, such as nifuroxazide and C16, in the treatment of cancer. Therapeutic compositions are provided that may be used to prevent, treat, or ameliorate the effects of a targeted cancer. Methods of using such compositions are also disclosed, such as methods of using the therapeutic compositions for improving efficacy of an oncolytic virotherapy (and for preventing macrophage and microglia inhibition of oncolytic viral activity).
    Type: Application
    Filed: February 18, 2017
    Publication date: October 10, 2019
    Applicant: VIROGIN BIOTECH CANADA LTD
    Inventors: William Jia, Zahid Delwar
  • ONCOLYTIC HERPES SIMPLEX VIRUS VECTORS EXPRESSING IMMUNE SYSTEM-STIMULATORY MOLECULES
    Publication number: 20190169253
    Abstract: An HSV vector comprising an expression cassette for one or more of IL12, IL15, and hIL15Receptor alpha subunit is provided.
    Type: Application
    Filed: August 1, 2017
    Publication date: June 6, 2019
    Applicant: VIROGIN BIOTECH CANADA LTD
    Inventors: William Jia, Guoyu Liu, Erica Lee, Dmitry Chouljenko, Jun Ding